fadE18

acyl-CoA dehydrogenase

Overview

Drug Classes: clofazimine
Organisms: Mycobacterium tuberculosis
Papers: 2
Mutations: 2

Mutations

Protein Change	Nucleotide Change	Mechanism	Organism	Resistance To	Database	Validation Status
R203D	-	-	Mycobacterium tuberculosis	clofazimine	Reslit	Candidate
-	C-150T	-	Mycobacterium tuberculosis	-	Reslit	Candidate

Papers2

Emergence of Canonical and Noncanonical Genomic Variants following In Vitro Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or Clofazimine.

PMID 36892309 · 2023

variants in fadE18 were identified in clofazimine-resistant mutants

Mutation Information

fadE18: p.R203D

Protein Change: R203D
Organisms: Mycobacterium tuberculosis
Confers Resistance To: clofazimine
Validation Method: whole-genome sequencing
Source Database: Reslit

Mce3R Stress-Resistance Pathway Is Vulnerable to Small-Molecule Targeting That Improves Tuberculosis Drug Activities.

PMID 31012313 · 2019

The fadE18 mutation contributes to 6-azasteroid resistance by reducing gene expression.

Mutation Information

fadE18: c.C-150T

Nucleotide Change: C-150T
Organisms: Mycobacterium tuberculosis
Validation Method: mutant experiment and transcriptional profiling
Source Database: Reslit

fadE18

Mutations

Mutation Information

Mutation Information

Browse AMR Genes

fadE18

Mutations

Mutation Information

Mutation Information